What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?
December 23, 2025 |
Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.
Lucy McKay Megan Pullein
CEO Strategic Operations Officer
Medics for Rare Disease Medics for Rare Disease
Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?
Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.
Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.
Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?
Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.
Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?
Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.
Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.
Christy: Where does the work for each group start, and where does it end?
Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?
The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.
The final phase will be to consolidate this evidence into concrete recommendations.
Christy: What do you find most exciting about RDI-Lancet Commission?
Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.
It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.
Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.
For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract
About Medscape Education
Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional
This content was provided by Medscape Education
Company Details
Latest Content from Medscape Education
The Lasting Impact of Cytomegalovirus Education
Education on the signs, symptoms, and potential complications of cytomegalovirus (CMV) is in need of constant development, as this common disease affects nearly 1 in 3 children by age 5...
Medscape Education Publishes the Results of Multinational, Multispecialty Survey of Physicians on Rare Disease Educational Needs
Medscape Education has published the results of a global survey of its kind, assessing the educational needs of physicians on rare diseases. This survey of 978 clinicians worldwide across 16...
Medscape Showcases Outcomes in Austria for EASL Congress
Medscape recently attended the EASL Congress in Austria, where they successfully showcased the outcomes of their Wilson Disease education program. One of their achievements was presenting a poster on "Online...
Medscape is Bringing Outcomes to the #HomeOfNeurology
Budapest, Hungary is set to become Medscape's next destination as they gear up for the highly anticipated 9th Annual Congress of the European Academy of Neurology. As an integral part...
Medscape Education: ACOG 2023 Publication
Medscape Education is making a difference! We are wrapping CMV Awareness Month with a look at the impact of CMV education on OB/GYN learners. Take a look as Medscape Senior...
It’s the Era of Outcomes at ERA 2023
The Medscape team has bid farewell to the beautiful city of Milano, Italy and our European nephrology colleagues. The team was thrilled to meet up with so many ground-breaking clinicians,...
International NASH Day 2023
Shari Dermer, PhD of Medscape Education, hosted Michael Betel, Founder and President of Fatty Liver Alliance, in an engaging conversation around the importance of NASH awareness, diagnosis, and prognosis. Listen...
Shining a Spotlight on Patient Centricity in Frankfurt for EHA
The Medscape Oncology team has made their way back from Frankfurt, Germany after another successful EHA 2023 conference. While at the event, the team interacted with conference attendees at the...
Skylines and Oncology Headlines in Chicago for ASCO 2023
ASCO 2023 was a huge success for Medscape Oncology with connections made with members and conference attendees during the event at the Medscape Oncology booth on the exhibit floor and...
Medscape Oncology and American Society of Clinical Oncology Collaborate to Offer Cancer-Specific Training to Multidisciplinary Members of the Oncology Care Team
This week Medscape Oncology announced an exciting collaboration with ASCO® which you read on the Cision PR news wire here or below:The American Society of Clinical Oncology (ASCO®), a leader at...